<DOC>
	<DOCNO>NCT01609452</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability blisibimod administer top standard-of-care subject Immune Thrombocytopenic Purpura ( ITP ) .</brief_summary>
	<brief_title>MONICA-SC : A Study Evaluate Efficacy , Safety Tolerability Blisibimod ( A-623 ) Administration Subjects With ITP</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . 18 75 year age ( male female ) . 2 . Diagnosis ITP accord guideline American Society Hematology ( ASH ) British Committee Standards Hematology . 3 . Platelet count Screening 30 billion/L less subject ITP medication , 50 billion/L less subject receive stable background ITP medication . 1 . Subjects splenectomy reason . 2 . Currently receive highdose ITP medication , eltrombopag , romiplostim , rituximab , investigational therapeutic agent . 3 . Nursing pregnant . 4 . Active infection require hospitalization treatment parenteral antibiotic within past 60 day . 5 . Any known history bone marrow stem cell disorder . 6 . Active hepatitis B , active hepatitis C document history HIV , hepatitis B , hepatitis C. 7 . Liver disease . 8 . Malignancy within past 5 year . 9 . History active tuberculosis ( TB ) history TB infection . 10 . Subject yet complete least 3 month 5 halflives ( whichever longer ) since end investigational study . 11 . History congenital immunodeficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Immune Thrombocytopenic Purpura</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Chronic ITP</keyword>
</DOC>